ArticleCancer cell2016
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 2 pooled it
14.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
169 citing papers in PubMed, 2 syntheses or guidelines pooled it, 283 citations in OpenAlex.
- Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review.International journal of molecular sciences · 2021Pooled it
- Trial
- Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.Clinical epigenetics · 2019Trial
- Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency.Nature genetics · 2026Article
- PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression.Cancer gene therapy · 2026Article
- Current Research in Polypharmacology for Cancer Treatment Using Dual-Target Histone Deacetylase Inhibitors.International journal of molecular sciences · 2026Review
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- Combining anti-gene γPNA with small molecules and RNA inhibitors: A strategy to enhance anti-tumor efficacy.Molecular therapy. Nucleic acids · 2026Article
- Medulloblastoma in Adolescents and Young Adults: Molecular Subgroups, Prognostic Biomarkers, and Age-Specific Therapeutic Challenges.Current issues in molecular biology · 2026Review
- HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges.Frontiers in cell and developmental biology · 2026Review
- Epigenetic regulation in medulloblastoma: from tumor heterogeneity to diagnostic, prognostic, and translational applications.Frontiers in molecular neuroscience · 2026Review
- Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma.Nature communications · 2025Article
- An Integrative Drug-Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations.Molecular carcinogenesis · 2025Article
- The role of DNA methylation in directing treatment in medulloblastoma.Epigenomics · 2025Review
- Advancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments.Brain sciences · 2025Review
- CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond.Science advances · 2025Review
- Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival.Nature communications · 2025Article
- The dual HDAC/PI3K inhibitor CUDC-907 inhibits the growth and proliferation of MYC-driven Group 3 medulloblastoma.Cell death discovery · 2025Article
- Lactylation in cancer: metabolic mechanism and therapeutic strategies.Cell death discovery · 2025Review
109 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 8 institutions in 3 countries.
Yanxin PeiTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Cancer and Immunology Department, Brain Tumor Institute, Children's National Medical Center, Washington, DC 20010, USA.
Kun-Wei LiuTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Jun WangTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Alexandra GarancherTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Ran TaoCancer and Immunology Department, Brain Tumor Institute, Children's National Medical Center, Washington, DC 20010, USA.
Lourdes A EsparzaTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Donna L MaierTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Yoko T UdakaDepartment of Pediatrics, University of California San Diego - Rady Children's Hospital, San Diego, CA 92123, USA.
Najiba MuradCancer and Immunology Department, Brain Tumor Institute, Children's National Medical Center, Washington, DC 20010, USA.
Sorana MorrissyProgram in Developmental and Stem Cell Biology, Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
Huriye Seker-CinDivision of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg, Germany.
Sebastian BrabetzDivision of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg, Germany.
Lin QiBrain Tumor Program, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Mari KogisoBrain Tumor Program, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Simone SchubertDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
James M OlsonFred Hutchinson Cancer Research Center, Seattle Children's Hospital, Seattle, WA 98109, USA.
Yoon-Jae ChoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xiao-Nan LiBrain Tumor Program, Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
John R CrawfordDepartment of Pediatrics, University of California San Diego - Rady Children's Hospital, San Diego, CA 92123, USA; Department of Neurosciences, University of California San Diego - Rady Children's Hospital, San Diego, CA 92123, USA.
Michael L LevyDepartment of Neurosurgery, University of California San Diego - Rady Children's Hospital, San Diego, CA 92123, USA.
Marcel KoolDivision of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg, Germany.
Stefan M PfisterDivision of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; German Cancer Consortium, Core Center, 69120 Heidelberg, Germany.
Michael D TaylorProgram in Developmental and Stem Cell Biology, Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada; Division of Neurosurgery, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
Robert J Wechsler-ReyaTumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Electronic address: rwreya@sbpdiscovery.org.
Sanford Burnham Prebys Medical Discovery Institute · USGerman Cancer Research Center · DEBaylor College of Medicine · USChildren's National · USUniversity of California San Diego · USHospital for Sick Children · CAStanford University · USSeattle Children's Hospital · US
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2MMouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4MTesting a cancer patient-specific SARS-CoV-2 vaccine in chemotherapy- and radiation-treated pediatric brain tumor mouse modelsR01CA114567 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI OLSON, JAMES M · 2006 to 2023
$4.9MChlorotoxin as a Targeting Agent for Cancer TherapiesR01CA135491 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI OLSON, JAMES M · 2008 to 2018
$3.8MStem Cells, Progenitors, and the Origin of MedulloblastomaR01CA122759 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WECHSLER-REYA, ROBERT J. · 2009 to 2013
$1.8MNCI NIH HHS CA030199NCI NIH HHS CA122759NCI NIH HHS CA159859NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA114567NCI NIH HHS R01 CA122759NCI NIH HHS R01 CA135491NCI NIH HHS R01 CA159859
Abstract
Medulloblastoma (MB) is a highly malignant pediatric brain tumor. Despite aggressive therapy, many patients succumb to the disease, and survivors experience severe side effects from treatment. MYC-driven MB has a particularly poor prognosis and would greatly benefit from more effective therapies. We used an animal model of MYC-driven MB to screen for drugs that decrease viability of tumor cells. Among the most effective compounds were histone deacetylase inhibitors (HDACIs). HDACIs potently inhibit survival of MYC-driven MB cells in vitro, in part by inducing expression of the FOXO1 tumor suppressor gene. HDACIs also synergize with phosphatidylinositol 3-kinase inhibitors to inhibit tumor growth in vivo. These studies identify an effective combination therapy for the most aggressive form of MB.
Indexed as
Phosphoinositide-3 Kinase InhibitorsAnimalsCell ProliferationDisease Models, AnimalForkhead Transcription FactorsGenes, Tumor SuppressorHistone Deacetylase InhibitorsHistone DeacetylasesHumansMedulloblastomaMiceMice, Inbred C57BLProto-Oncogene Proteins c-mycForkhead Transcription FactorsHistone Deacetylase InhibitorsHistone DeacetylasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-myc
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.